{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T15:23:47Z","timestamp":1778081027556,"version":"3.51.4"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T00:00:00Z","timestamp":1565654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T00:00:00Z","timestamp":1565654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Low-density-lipoprotein cholesterol (LDL-c) guides lipid-lowering therapy, although other lipid parameters could better reflect cardiovascular disease (CVD) risk. Discordance between these parameters and LDL-c has not been evaluated in metabolic syndrome (MetS) patients. We characterized a comprehensive lipid profile in 177 MetS patients. The 2016 ESC\/EAS Guidelines for the Management of Dyslipidemias were used to define LDL-c targets. The atherogenic lipoprotein profile was compared in patients with LDL-c within and above the target. Only 34.4% (61) of patients had mean LDL-c levels within the guidelines and patients with LDL-c above target presented significantly elevated levels of Apolipoprotein B (ApoB), non-high-density lipoprotein cholesterol (non-HDL-c) and oxidized LDL-c. In patients with LDL-c within target, 25%, 31% and 49% presented levels above the recommended range for ApoB, non-HDL-c and oxidized LDL-c, respectively. Patients presented a strong association of LDL-c and non-HDL-c (r\u2009=\u20090.796), ApoB (r\u2009=\u20090.749) and oxidized LDL-c (r\u2009=\u20090.452). Similarly, non-HDL-c was strongly correlated with ApoB (r\u2009=\u20090.857) and oxidized-LDL-c (r\u2009=\u20090.555). The logistic regression model evidenced higher triglycerides and HDL-c and lower ApoB as predictors of having LDL-c within target. Reliance solely on LDL-c could result in missed opportunities for CVD risk reduction. ApoB, oxidized LDL-c, and particularly non-HDL-c, could be valuable parameters to estimate the CVD risk of MetS patients and have the potential to be targeted therapeutically.<\/jats:p>","DOI":"10.1038\/s41598-019-48120-5","type":"journal-article","created":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T10:02:28Z","timestamp":1565690548000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["Novel and traditional lipid profiles in Metabolic Syndrome reveal a high atherogenicity"],"prefix":"10.1038","volume":"9","author":[{"given":"S\u00edlvia","family":"Paredes","sequence":"first","affiliation":[]},{"given":"Liliana","family":"Fonseca","sequence":"additional","affiliation":[]},{"given":"Laura","family":"Ribeiro","sequence":"additional","affiliation":[]},{"given":"Helena","family":"Ramos","sequence":"additional","affiliation":[]},{"given":"Jos\u00e9 Carlos","family":"Oliveira","sequence":"additional","affiliation":[]},{"given":"Isabel","family":"Palma","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2019,8,13]]},"reference":[{"key":"48120_CR1","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa050461","volume":"352","author":"JC LaRosa","year":"2005","unstructured":"LaRosa, J. C. et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. The New England journal of medicine 352, 1425\u20131435 (2005).","journal-title":"The New England journal of medicine"},{"key":"48120_CR2","doi-asserted-by":"crossref","unstructured":"Taylor, F. et al. Statins for the primary prevention of cardiovascular disease. The Cochrane database of systematic reviews, CD004816 (2013).","DOI":"10.1002\/14651858.CD004816.pub5"},{"key":"48120_CR3","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","volume":"37","author":"AL Catapano","year":"2016","unstructured":"Catapano, A. L. et al. 2016 ESC\/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J 37, 2999\u20133058 (2016).","journal-title":"Eur Heart J"},{"key":"48120_CR4","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.jacl.2013.11.001","volume":"8","author":"M Kilgore","year":"2014","unstructured":"Kilgore, M. et al. Discordance between high non-HDL cholesterol and high LDL-cholesterol among US adults. J Clin Lipidol 8, 86\u201393 (2014).","journal-title":"J Clin Lipidol"},{"key":"48120_CR5","doi-asserted-by":"publisher","first-page":"208","DOI":"10.3803\/EnM.2015.30.2.208","volume":"30","author":"Y Lim","year":"2015","unstructured":"Lim, Y. et al. Apolipoprotein B Is Related to Metabolic Syndrome Independently of Low Density Lipoprotein Cholesterol in Patients with Type 2 Diabetes. Endocrinol Metab (Seoul) 30, 208\u2013215 (2015).","journal-title":"Endocrinol Metab (Seoul)"},{"key":"48120_CR6","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1007\/s11886-002-0113-6","volume":"4","author":"G Ruotolo","year":"2002","unstructured":"Ruotolo, G. & Howard, B. V. Dyslipidemia of the metabolic syndrome. Curr Cardiol Rep 4, 494\u2013500 (2002).","journal-title":"Curr Cardiol Rep"},{"key":"48120_CR7","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1159\/000442721","volume":"8","author":"V Yumuk","year":"2015","unstructured":"Yumuk, V. et al. European Guidelines for Obesity Management in Adults. Obes Facts 8, 402\u2013424 (2015).","journal-title":"Obes Facts"},{"key":"48120_CR8","doi-asserted-by":"crossref","unstructured":"Mancia, G. et al. ESH\/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 34, (2013).","DOI":"10.1093\/eurheartj\/eht151"},{"key":"48120_CR9","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.2337\/dc18-S002","volume":"41","author":"American Diabetes, A. 2","year":"2018","unstructured":"American Diabetes, A. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2018. Diabetes Care 41, S13\u2013S27 (2018).","journal-title":"Diabetes Care"},{"key":"48120_CR10","first-page":"1640","volume-title":"Circulation","author":"KG Alberti","year":"2009","unstructured":"Alberti, K. G. et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120, (1640\u20131645 (2009)."},{"key":"48120_CR11","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","volume":"18","author":"WT Friedewald","year":"1972","unstructured":"Friedewald, W. T., Levy, R. I. & Fredrickson, D. S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18, 499\u2013502 (1972).","journal-title":"Clin Chem"},{"key":"48120_CR12","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1161\/CIRCULATIONAHA.112.128413","volume":"127","author":"NJ Pagidipati","year":"2013","unstructured":"Pagidipati, N. J. & Gaziano, T. A. Estimating deaths from cardiovascular disease: a review of global methodologies of mortality measurement. Circulation 127, 749\u2013756 (2013).","journal-title":"Circulation"},{"key":"48120_CR13","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1001\/jama.2012.366","volume":"307","author":"SM Boekholdt","year":"2012","unstructured":"Boekholdt, S. M. et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA 307, 1302\u20131309 (2012).","journal-title":"JAMA"},{"key":"48120_CR14","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1161\/CIRCOUTCOMES.110.959247","volume":"4","author":"AD Sniderman","year":"2011","unstructured":"Sniderman, A. D. et al. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes 4, 337\u2013345 (2011).","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"48120_CR15","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1089\/met.2010.0006","volume":"8","author":"I Boumaiza","year":"2010","unstructured":"Boumaiza, I. et al. Apolipoprotein B and non-high-density lipoprotein cholesterol are better risk markers for coronary artery disease than low-density lipoprotein cholesterol in hypertriglyceridemic metabolic syndrome patients. Metab Syndr Relat Disord 8, 515\u2013522 (2010).","journal-title":"Metab Syndr Relat Disord"},{"key":"48120_CR16","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s40200-017-0306-6","volume":"16","author":"S Ghodsi","year":"2017","unstructured":"Ghodsi, S. et al. Non-high-density lipoprotein fractions are strongly associated with the presence of metabolic syndrome independent of obesity and diabetes: a population-based study among Iranian adults. J Diabetes Metab Disord 16, 25 (2017).","journal-title":"J Diabetes Metab Disord"},{"key":"48120_CR17","doi-asserted-by":"publisher","first-page":"931","DOI":"10.2310\/JIM.0b013e318182080a","volume":"56","author":"J Huang","year":"2008","unstructured":"Huang, J. et al. Non-high-density lipoprotein cholesterol in patients with metabolic syndrome. J Investig Med 56, 931\u2013936 (2008).","journal-title":"J Investig Med"},{"key":"48120_CR18","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.jacl.2014.11.005","volume":"9","author":"SA Varvel","year":"2015","unstructured":"Varvel, S. A. et al. Discordance between apolipoprotein B and low-density lipoprotein particle number is associated with insulin resistance in clinical practice. J Clin Lipidol 9, 247\u2013255 (2015).","journal-title":"J Clin Lipidol"},{"key":"48120_CR19","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.hlc.2016.04.025","volume":"25","author":"Y Zhang","year":"2016","unstructured":"Zhang, Y. et al. Non-HDL-C is a Better Predictor for the Severity of Coronary Atherosclerosis Compared with LDL-C. Heart Lung Circ 25, 975\u2013981 (2016).","journal-title":"Heart Lung Circ"},{"key":"48120_CR20","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1161\/ATVBAHA.110.204669","volume":"30","author":"N Mattsson","year":"2010","unstructured":"Mattsson, N. et al. Metabolic syndrome and carotid intima-media thickness in young adults: roles of apolipoprotein B, apolipoprotein A-I, C-reactive protein, and secretory phospholipase A2: the cardiovascular risk in young Finns study. Arterioscler Thromb Vasc Biol 30, 1861\u20131866 (2010).","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"48120_CR21","doi-asserted-by":"publisher","first-page":"e0182217","DOI":"10.1371\/journal.pone.0182217","volume":"12","author":"MS Borja","year":"2017","unstructured":"Borja, M. S. et al. Apolipoprotein A-I exchange is impaired in metabolic syndrome patients asymptomatic for diabetes and cardiovascular disease. PLoS ONE 12, e0182217 (2017).","journal-title":"PLoS One"},{"key":"48120_CR22","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1111\/j.1365-2796.2006.01643.x","volume":"259","author":"G Walldius","year":"2006","unstructured":"Walldius, G. & Jungner, I. The apoB\/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy\u2013a review of the evidence. J Intern Med 259, 493\u2013519 (2006).","journal-title":"J Intern Med"},{"key":"48120_CR23","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.numecd.2009.11.002","volume":"21","author":"GP Carnevale Schianca","year":"2011","unstructured":"Carnevale Schianca, G. P. et al. ApoB\/apoA-I ratio is better than LDL-C in detecting cardiovascular risk. Nutr Metab Cardiovasc Dis 21, 406\u2013411 (2011).","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"48120_CR24","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1161\/01.STR.0000140629.65145.3c","volume":"35","author":"K Wallenfeldt","year":"2004","unstructured":"Wallenfeldt, K., Bokemark, L., Wikstrand, J., Hulthe, J. & Fagerberg, B. Apolipoprotein B\/apolipoprotein A-I in relation to the metabolic syndrome and change in carotid artery intima-media thickness during 3 years in middle-aged men. Stroke 35, 2248\u20132252 (2004).","journal-title":"Stroke"},{"key":"48120_CR25","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.cdtm.2017.02.008","volume":"3","author":"S Gao","year":"2017","unstructured":"Gao, S. & Liu, J. Association between circulating oxidized low-density lipoprotein and atherosclerotic cardiovascular disease. Chronic Dis Transl Med 3, 89\u201394 (2017).","journal-title":"Chronic Dis Transl Med"},{"key":"48120_CR26","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1161\/01.ATV.0000080379.05071.22","volume":"23","author":"P Holvoet","year":"2003","unstructured":"Holvoet, P. et al. Association of high coronary heart disease risk status with circulating oxidized LDL in the well-functioning elderly: findings from the Health, Aging, and Body Composition study. Arterioscler Thromb Vasc Biol 23, 1444\u20131448 (2003).","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"48120_CR27","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.lfs.2016.02.002","volume":"148","author":"V Rani","year":"2016","unstructured":"Rani, V., Deep, G., Singh, R. K., Palle, K. & Yadav, U. C. Oxidative stress and metabolic disorders: Pathogenesis and therapeutic strategies. Life Sci 148, 183\u2013193 (2016).","journal-title":"Life Sci"},{"key":"48120_CR28","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.2337\/diabetes.53.4.1068","volume":"53","author":"P Holvoet","year":"2004","unstructured":"Holvoet, P. et al. The metabolic syndrome, circulating oxidized LDL, and risk of myocardial infarction in well-functioning elderly people in the health, aging, and body composition cohort. Diabetes 53, 1068\u20131073 (2004).","journal-title":"Diabetes"},{"key":"48120_CR29","doi-asserted-by":"publisher","first-page":"474","DOI":"10.2337\/db16-0933","volume":"66","author":"Y Hurtado-Roca","year":"2017","unstructured":"Hurtado-Roca, Y. et al. Oxidized LDL Is Associated With Metabolic Syndrome Traits Independently of Central Obesity and Insulin Resistance. Diabetes 66, 474\u2013482 (2017).","journal-title":"Diabetes"},{"key":"48120_CR30","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1016\/j.jacc.2013.06.051","volume":"62","author":"JJ Albers","year":"2013","unstructured":"Albers, J. J. et al. Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL\/High Triglyceride and Impact on Global Health Outcomes). J Am Coll Cardiol 62, 1575\u20131579 (2013).","journal-title":"J Am Coll Cardiol"},{"key":"48120_CR31","unstructured":"Hippe, D. S. et al. Lp(a) (Lipoprotein(a)) Levels Predict Progression of Carotid Atherosclerosis in Subjects With Atherosclerotic Cardiovascular Disease on Intensive Lipid Therapy: An Analysis of the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL\/High Triglycerides: Impact on Global Health Outcomes) Carotid Magnetic Resonance Imaging Substudy-Brief Report. Arterioscler Thromb Vasc Biol 38, 673-678, (2018)."},{"key":"48120_CR32","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1079\/PNS19990022","volume":"58","author":"BA Griffin","year":"1999","unstructured":"Griffin, B. A. Lipoprotein atherogenicity: an overview of current mechanisms. Proc Nutr Soc 58, 163\u2013169 (1999).","journal-title":"Proc Nutr Soc"},{"key":"48120_CR33","first-page":"228","volume":"4","author":"KE Watson","year":"2003","unstructured":"Watson, K. E., Horowitz, B. N. & Matson, G. Lipid abnormalities in insulin resistant states. Rev Cardiovasc Med 4, 228\u2013236 (2003).","journal-title":"Rev Cardiovasc Med"},{"key":"48120_CR34","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/dmrr.694","volume":"23","author":"M Rizzo","year":"2007","unstructured":"Rizzo, M. & Berneis, K. Small, dense low-density-lipoproteins and the metabolic syndrome. Diabetes Metab Res Rev 23, 14\u201320 (2007).","journal-title":"Diabetes Metab Res Rev"},{"key":"48120_CR35","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.atherosclerosis.2009.06.035","volume":"207","author":"J Vekic","year":"2009","unstructured":"Vekic, J. et al. Small, dense LDL cholesterol and apolipoprotein B: relationship with serum lipids and LDL size. Atherosclerosis 207, 496\u2013501 (2009).","journal-title":"Atherosclerosis"},{"key":"48120_CR36","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1136\/pgmj.2004.025601","volume":"81","author":"GD Kolovou","year":"2005","unstructured":"Kolovou, G. D., Anagnostopoulou, K. K. & Cokkinos, D. V. Pathophysiology of dyslipidaemia in the metabolic syndrome. Postgrad Med J 81, 358\u2013366 (2005).","journal-title":"Postgrad Med J"},{"key":"48120_CR37","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.2337\/diacare.27.12.3009","volume":"27","author":"ZT Bloomgarden","year":"2004","unstructured":"Bloomgarden, Z. T. Dyslipidemia and the metabolic syndrome. Diabetes Care 27, 3009\u20133016 (2004).","journal-title":"Diabetes Care"},{"key":"48120_CR38","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1515\/CCLM.2003.010","volume":"41","author":"P Brizzi","year":"2003","unstructured":"Brizzi, P. et al. Plasma lipid composition and LDL oxidation. Clin Chem Lab Med 41, 56\u201360 (2003).","journal-title":"Clin Chem Lab Med"},{"key":"48120_CR39","first-page":"569","volume":"54","author":"THT Hayashi","year":"2006","unstructured":"Hayashi, T. H. T., Shiobara, SuguroT. & Adachi, M. T. Small dense LDL concentration is closely associated with serum apolipoprotein B, comparisons of non-LDL cholesterol or LDL cholesterol. Rinsho Byori 54, 569\u2013575 (2006).","journal-title":"Rinsho Byori"},{"key":"48120_CR40","first-page":"434","volume":"55","author":"H T","year":"2007","unstructured":"T, H. Metabolic syndrome and small dense LDL-cholesterol. Rinsho Byori 55, 434\u2013438 (2007).","journal-title":"Rinsho Byori"},{"key":"48120_CR41","doi-asserted-by":"publisher","first-page":"240","DOI":"10.2337\/diacare.26.1.240","volume":"26","author":"SH Hsia","year":"2003","unstructured":"Hsia, S. H. Non-HDL cholesterol: into the spotlight. Diabetes Care 26, 240\u2013242 (2003).","journal-title":"Diabetes Care"},{"key":"48120_CR42","doi-asserted-by":"publisher","first-page":"16","DOI":"10.2337\/diacare.26.1.16","volume":"26","author":"W Lu","year":"2003","unstructured":"Lu, W. et al. Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: the strong heart study. Diabetes Care 26, 16\u201323 (2003).","journal-title":"Diabetes Care"},{"key":"48120_CR43","doi-asserted-by":"publisher","first-page":"171","DOI":"10.2147\/VHRM.S104369","volume":"12","author":"PP Toth","year":"2016","unstructured":"Toth, P. P. Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease. Vasc Health Risk Manag 12, 171\u2013183 (2016).","journal-title":"Vasc Health Risk Manag"},{"key":"48120_CR44","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0026-0495(00)90688-7","volume":"49","author":"G Leroux","year":"2000","unstructured":"Leroux, G. et al. Influence of triglyceride concentration on the relationship between lipoprotein cholesterol and apolipoprotein B and A-I levels. Metabolism 49, 53\u201361 (2000).","journal-title":"Metabolism"},{"key":"48120_CR45","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1309\/AJCPLHJBGG9L3ILS","volume":"136","author":"P Srisawasdi","year":"2011","unstructured":"Srisawasdi, P. et al. Estimation of plasma small dense LDL cholesterol from classic lipid measures. Am J Clin Pathol 136, 20\u201329 (2011).","journal-title":"Am J Clin Pathol"},{"key":"48120_CR46","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1161\/01.ATV.0000054658.91146.64","volume":"23","author":"PJ Barter","year":"2003","unstructured":"Barter, P. J. et al. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 23, 160\u2013167 (2003).","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"48120_CR47","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.jacc.2015.10.055","volume":"67","author":"JT Wilkins","year":"2016","unstructured":"Wilkins, J. T., Li, R. C., Sniderman, A., Chan, C. & Lloyd-Jones, D. M. Discordance Between Apolipoprotein B and LDL-Cholesterol in Young Adults Predicts Coronary Artery Calcification: The CARDIA Study. J Am Coll Cardiol 67, 193\u2013201 (2016).","journal-title":"J Am Coll Cardiol"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-48120-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-48120-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-48120-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T12:31:28Z","timestamp":1671280288000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-48120-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,13]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["48120"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-48120-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,13]]},"assertion":[{"value":"25 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"11792"}}